NewsBenzingaRBC Capital mantiene su recomendación de sobreponderar sobre Amgen y eleva el precio objetivo a 470 dólares. RBC Capital mantiene su recomendación de sobreponderar sobre Amgen y eleva el precio objetivo a 470 dólares. Benzinga 2026.11.04 16:14 (GMT+0) Open on Benzinga Other news How Tokenized Nvidia Traded Through Two Weeks of Huang Headlines What Are Wall Street Analysts' Target Price for Lumentum Holdings Stock? Texas Pacific Land Stock: Analyst Estimates & Ratings Keybanc Reiterates Sector Weight on NVIDIAto Sector Weight Top 3 Tech Stocks That May Fall Off A Cliff This Month Truist Securities Maintains Hold on BILL Holdings, Raises Price Target to $66